SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Sareum to Participate in the Edison Group's Global Healthcare "Open House" Virtual Conference (25-27 January 2022)

Cambridge, UK, 25 January 2022 - Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development company, announces that the Company will be participating in Edison Group's Global Healthcare "Open House" Virtual Conference, taking place on 25-27 January 2022.

At the event, Sareum's Chief Executive Officer, Dr Tim Mitchell, will take part in a virtual interview to discuss the Company's progress and strategy in 2022 with its lead TYK2/JAK1 inhibitor assets SDC-1801 and SDC-1802, as well as opportunities under consideration by licensee Sierra Oncology to advance Chk1 inhibitor SRA737. Dr Mitchell's interview will form part of the pharmaceuticals and drug discovery session, scheduled to take place between 08:00 and 16:00 GMT on Tuesday 25 January. Sareum's content will be available on demand on www.edisongroup.com from 8:00am GMT on Tuesday 25 January. No material new information will be made available.

Edison Group's Global Healthcare "Open House" Virtual Conference is a three-day event hosted in association with the London Stock Exchange, global law firm Taylor Wessing and OpenExchange, and will focus on 33 companies. Day one will feature businesses within pharmaceuticals & drug discovery; day two focuses on novel approaches to hard-to-solve problems; and businesses adopting AI & technology in healthcare will round off the event on day three.

Attendance is free and more information about the event, including how to register to attend, can be found by clicking here.

1x1 Meeting Registration: To register for a 1x1 meeting with the Company, please visit this link.  

For further information, please contact: 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com  

- Ends -